|
Identifying BRAF Mutation Assists in Targeted Metastatic Melanoma Therapy |
|
Tuesday, 31 August 2010 13:24 |
|
The identification of somatic mutations in gene encoding the serine-threonine protein kinase B-RAF (BRAF) in melanomas offers an opportunity to test oncogene-targeted therapy for this disease, according to a study funded by Plexxikon and Roche Pharmaceuticals.
Results from the study were published in the August 26 issue of the New England Journal of Medicine.
|
|
Read more...
|
|
|
NCCN Receives $2 Million Grants for Cancer Treatment Studies |
|
Thursday, 12 August 2010 13:16 |
|
The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical studies of ofatumumab (Arzerra®, GlaxoSmithKline) in the treatment of hematologic malignancies and pazopanib (Votrient®, GlaxoSmithKline) in the treatment of solid tumors.
|
|
Read more...
|
|
Nilotinib Receives Front-Line Treatment Approval for CML |
|
Wednesday, 11 August 2010 13:07 |
|
The US Food and Drug Administration (FDA) has approved nilotinib (Tasigna, Novartis) as a first-line treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
|
|
Read more...
|
|
Experts Issue New Guidelines on Breast Cancer Drugs |
|
Wednesday, 14 July 2010 08:50 |
A group of cancer experts issued new guidelines on the best way to use two classes of hormone therapies for estrogen receptor-positive breast cancer.
|
|
Read more...
|
|
US Cancer Death Rates Declining |
|
Friday, 09 July 2010 09:31 |
|
According to the annual statistics report by the American Cancer Society (ACS) cancer death rates in the United States continue to decline mainly because of falling smoking rates, improved cancer treatments, and earlier detection.
|
|
Read more...
|
|
|
|
|
<< Start < Prev 1 2 3 4 5 Next > End >>
|
|
Page 1 of 5 |
